Table 1.
Demographic and Clinical Characteristics of a Population-Based Cohort of Hepatitis B Virus (HBV) Infected Alaska Native Males Aged <40 Years and Females Aged <50 Years By HBV Genotype/Subgenotype — Alaska, 1982–2012.a
| Characteristic | HBV Genotype/Subgenotype | Total | P-valueb | |||||
|---|---|---|---|---|---|---|---|---|
| A2 (n=135) | B6 (n=18) | C2 (n=57) | D (n=538) | F1 (n=201) | Unknown (n=134) | (n=1083) | ||
| % Male | 58% | 56% | 42% | 56% | 58% | 57% | 56% | 0.31 |
| Median age (range) at first +HBsAg, years | 19.8 (2.4–49.1) | 25.2 (8.1–47.6) | 17.6 (1.0–45.2) | 14.2 (0–49.2) | 8.7 (0–49.0) | 21.9 (1.6–48.1) | 15.6 (0–49.2) | <0.01 |
| Median age (range) at cohort entry, years | 21.0 (2.4–49.2) | 30.9 (13.0–47.6) | 19.1 (1.0–46.5) | 15.6 (0–49.2) | 14.7 (1.7–49.6) | 23.4 (1.6–49.6) | 18.0 (0–49.6) | <0.01 |
| % died during study period | 10% | 11% | 11% | 12% | 17% | 13% | 13% | 0.31 |
| % aged out of cohortc | 65% | 83% | 61% | 48% | 47% | 63% | 53% | |
| % currently eligibled | 25% | 6% | 28% | 40% | 36% | 24% | 34% | <0.01 |
| Median age (range) of currently eligible, years | 42.3 (31.6–49.7) | 46.4 | 35.3 (22.4–47.9) | 35.2 (20.4–49.6) | 38.0 (30.9–49.4) | 39.8 (31.1–49.6) | 36.6 (20.4–49.7) | <0.01 |
| % developing HCC | 0.7% | 0 | 0 | 0.4% | 9.5% | 0 | 2.0% | <0.01 |
| Median age (range) at HCC diagnosis, years | 32.8 | -- | -- | 23.6 (17.0–30.1) | 19.9 (8.6–40.2) | -- | 20.8 (8.6–40.2) | 1.0 |
| Total person-years of follow-upe | 2605 | 253 | 1142 | 11604 | 4341 | 2354 | 22300 | |
| Median (range) person-years of follow-up | 20.4 (0.8–31.0) | 12.1 (2.0–31) | 21.1 (2.1–31) | 25.9 (<0.1–31) | 24.1 (0.1–31) | 18.2 (<0.1–31) | 23.4 (<0.1–31) | |
Abbreviations: HBsAg, positive hepatitis B surface antigen; HCC, hepatocellular carcinoma
Analysis restricted to men aged <40 years and women aged <50 years at cohort entry
Equality of medians test comparing medians, Chi-squared or randomization test for proportions (significant results indicated in bold).
Males and females attaining age 40 and 50 years, respectively, before end of study period
Alive at end of study period and not aged out of cohort
Person-years of follow-up calculated from cohort entry until death, HCC diagnosis, aged out of cohort, or end of study period